BRIEF COMMUNICATIONIntravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients—Results from a proof-of-concept study
Under a Creative Commons license
open archive
KEYWORDS
antibiotic: antiviral
clinical research/practice
complication: infectious
infection and infectious agents – viral: BK/JC/polyoma
infectious disease
kidney transplantation/nephrology
Abbreviations
AMR
antibody-mediated rejection
AUC
area under the concentration-time curve
BKV
BK virus
BKVAN
BKV-associated nephropathy
Day 0
day of transplantation
DSA
donor-specific antibodies
IgG
immunoglobulin G
IVIg
intravenous immunoglobulin
KT
kidney transplantation
KTR
kidney transplant recipients
MMF
mycophenolate mofetil
mTOR
mammalian target of rapamycin
NAb
neutralizing antibodies
PRA
panel reactive antibody
SD
standard deviation
SID
secondary immunodeficiency
Cited by (0)
[Correction added on 4 December, 2020, after first online publication: In the abstract, “from developing” has been removed in the sentence: “We investigated whether early IVIg administration prevents BKV replication in patients with low NAb titers (<4 log10 against the BKV-specific genotype); The word “intravenous immunoglobulins” has been corrected to “intravenous immunoglobulin” in all occurrence]
Copyright © 2021 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.